Curio Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Curio Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$113	–	216
2026 Q1	$113	Buy	+2	New	+$117	﹤0.01%	946

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Curio Wealth's BMRN Position: Q2 2026 in Review

Curio Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 2 shares — an estimated $113 sold.

Curio Wealth first reported a position in BMRN in Q1 2026 and held it in 1 quarter. The position peaked at $113 in Q1 2026. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Curio Wealth reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 2 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $113.
Curio Wealth first reported a position in BioMarin Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Curio Wealth's BioMarin Pharmaceuticals position peaked at $113 in Q1 2026.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.